Danaher Corporation vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Danaher Corporation trades at $201.22 (market cap $140.88B), while Direxion Daily S&P 500 Bull 3X Shares trades at $277.09. The key difference: Danaher Corporation pays a 0.8% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | SPXL | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $242.05 | $288.04 |
52-Week Low | $161.91 | $170.20 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
SPXL is trading at $272.66, down 2.34% today, with a bullish technical signal supported by moving averages. The stock faces resistance at $277-$283 while finding support at $270-$264 levels. Recent news highlights ongoing AI-driven market dynamics and earnings season catalysts that could influence S&P 500 performance.
Outlook remains cautiously optimistic with technical strength but requires monitoring of earnings results and market sentiment. Key risks include stretched valuations and potential market volatility during earnings season. The stock's performance remains tied to broader S&P 500 trends and AI sector developments.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →